In vivo and in vitro expression of the RASAL1 gene in human gastric adenocarcinoma and its clinicopathological significance

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 535-540

  Chen, Hong ^a   Yang, Xiao Wei ^a   Zhang, Hui ^a   Yang, Qing ^a   Wang, Zhi ^a   Liu, Yang ^a   Lu, Feng Lin ^a   Zhou, Bao Yi ^a   Qiu Xi, Cheng Hui ^a   Lu, Sheng Lin ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RAS PROTEIN ACTIVATOR LIKE 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; PRIMARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84862926042     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.513     Document Type: Article

References (21)

1. Parada LF, Tabin CJ, Shis C and Weinberg RA: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297: 474-478, 1982.
2. Fernández-Medarde A and Santos E: Ras in cancer and developmental diseases. Genes Cancer 2: 344-358, 2011.
3. Cox AD and Der CJ: Ras history: the saga continues. Small Gtpases 1: 2-27, 2010.
4. Jin H, Wang X, Ying J, Wong AH, Cui Y, Srivastava G, Shen ZY, Li EM, Zhang Q, Jin J, Kupzig S, Chan AT, Cullen PJ and Tao Q: Epigenetic silencing of Ca2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA 104: 12353-12358, 2007.
5. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T and Omata M: Decreased expression of the Ras GTPase-activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology 136: 206-216, 2009.
6. Bernards A and Settleman J: Loss of the Ras regulator RASAL1: another route to Ras activation in colorectal cancer. Gastroenterology 136: 46-48, 2009.
7. Wang YW, Qu Y, Li JF, Chen XH, Liu BY, Gu QL and Zhu ZG: In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity. Clin Cancer Res 12: 4965-4973, 2006.
8. Malumbres M and Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465, 2003.
9. Karnoub AE and Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531, 2008.
10. Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N and Matsubara N: No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. J Int Med Res 35: 450-457, 2007.
11. Liu ZM, Liu LN, Li M, Zhang QP, Cheng SH and Lu S: Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer. Oncol Rep 22: 515-520, 2009.
12. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM and Thorgeirsson SS: Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 54: 311-319, 2011.
13. Kong Z, Xie D, Boike T, Raghavan P, Burma S, Chen DJ, Habib AA, Chakraborty A, Hsieh JT and Saha D: Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res 70: 2829-2839, 2010.
14. Vigil D, Cherfils J, Rossman KL and Der CJ: Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10: 842-857, 2010.
15. Bos JL, Rehmann H and Wittinghofer A: GEFs and GAPs: critical elements in the control of small G proteins. Cell 129: 865-877, 2007.
16. Iwashita S and Song SY: Ras GAPs: a crucial regulator of extracellular stimuli for homeostasis of cellular functions. Mol Biosyst 4: 213-222, 2008.
17. Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R and Bernards R: NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142: 218-229, 2010.
18. Seto M, Ohta M, Ikenoue T, Sugimoto T, Asaoka Y, Tada M, Mohri D, Kudo Y, Ijichi H, Tateishi K, Otsuka M, Hirata Y, Maeda S, Koike K and Omata M: Reduced expression of RAS protein activator like-1 in gastric cancer. Int J Cancer 128: 1293-1302, 2011.
19. Liu Q, Walker SA, Gao D, Taylor JA, Dai YF, Arkell RS, Bootman MD, Roderick HL, Cullen PJ and Lockyer PJ: CAPRI and RASAL impose different modes of information processing on RAS due to contrasting temporal filtering of Ca2+. J Cell Biol 170: 183-190, 2005.
20. Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM and Agami R: A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121: 849-858, 2005.
21. Chen YN, Chen H, Xu Y, Zhang X and Luo Y: Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance. World J Gastroenterol 14: 292-297, 2008.